Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03YVO
|
|||
| Former ID |
DNAP001296
|
|||
| Drug Name |
Methylnaltrexone bromide
|
|||
| Synonyms |
Relistor; Methylnaltrexone (Bromide); Naltrexone methobromide; 73232-52-7; N-Methylnaltrexone Bromide; MRZ-2663BR; N-Cyclopropylmethyl-noroxymorphone Methobromide; Methylnaltrexone; MNTX; C21H26NO4Br; MOA-728; Relistor (TN); MRZ 2663BR; Naltrexone Methyl Bromide; N-Methyl Naltrexone Bromide; MNTX-302; SCHEMBL2798188; CHEMBL1201770; IFGIYSGOEZJNBE-KNLJMPJLSA-N; ONO-3849; Methylnaltrexone bromide (JAN/USAN); 3844AH; AKOS015896214; CS-0762; AN-37324; HY-75766; Methylnaltrexone bromide, > W-5330; CHIR-01020
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Opioid-induced constipation [ICD-11: DB32.1; ICD-10: K59.0; ICD-9: 564] | Approved | [1] | |
| Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Preclinical | [2] | ||
| Company |
Progenics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H26BrNO4
|
|||
| Canonical SMILES |
C[N+]1(CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6.[Br-]
|
|||
| InChI |
1S/C21H25NO4.BrH/c1-22(11-12-2-3-12)9-8-20-17-13-4-5-14(23)18(17)26-19(20)15(24)6-7-21(20,25)16(22)10-13;/h4-5,12,16,19,25H,2-3,6-11H2,1H3;1H/t16-,19+,20+,21-,22?;/m1./s1
|
|||
| InChIKey |
IFGIYSGOEZJNBE-KNLJMPJLSA-N
|
|||
| CAS Number |
CAS 73232-52-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ADReCS Drug ID | BADD_D01430 ; BADD_D02462 | |||
| SuperDrug ATC ID |
A06AH01
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Melanocortin receptor 4 (MC4R) | Target Info | Agonist | [2] |
| Opioid receptor mu (MOP) | Target Info | Modulator | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Estrogen signaling pathway | ||||
| Morphine addiction | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Enkephalin release | ||||
| Pathway Interaction Database | Syndecan-3-mediated signaling events | |||
| IL4-mediated signaling events | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (s) signalling events | ||||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| TCR Signaling Pathway | ||||
| Opioid Signalling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. | |||
| REF 2 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.